Name of the Project
Cipla biotech manufacturing facility project.
Location
The project will be located in the Dube TradePort special economic zone, in Durban, South Africa.
Client
Cipla Medpro, a subsidiary of Cipla.
Project Description
The project involves the construction of the country’s first state-of-the-art biotech manufacturing facility for the production of biosimilars. The facility will manufacture biosimilar drugs made from living organisms, which are used to treat cancer and other diseases. Biosimilars are designed to have the same characteristics as an original biological agent.
The biosimilars produced at the facility will be for State and private sectors and there is also the potential to export to markets in the US, the European Union and Asia.
Jobs to be Created
At full capacity, the facility is expected to create up to 300 jobs – 180 high-skilled jobs and 120 indirect jobs – primarily in the engineering and biological science fields.
Value
R1.3-billion.
Duration
Construction is scheduled to start in early 2017, with full operations expected to start in the third quarter of 2018.
Latest Developments
None stated.
Key Contracts and Suppliers
None stated.
On Budget and on Time?
Not stated.
Contact Details for Project Information
Cipla corporate communications, Charlotte Chunawala, tel +91 750 625 7377 or email charlotte.chunawala@cipla.com.